Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexfenfluramine. Its place in weight control.

P Turner1

  • 1Department of Clinical Pharmacology, St Bartholomew's Hospital, London, United Kingdom.

Drugs
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of NF-kappa B in the regulation of inducible nitric oxide synthase in an MTAL cell line.

The American journal of physiology·1995
Same author

Henderson-Hasselbalch equation is inadequate for the measurement of transmembrane diffusion of drugs and buccal drug absorption is a useful alternative.

General pharmacology·1995
Same author

Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis.

Lancet (London, England)·1995
Same author

Effect of ageing and propranolol administration on myocardial beta-adrenoceptor receptor function in mature rats.

European journal of pharmacology·1995
Same author

Identification of constitutive and inducible forms of nitric oxide synthase in human platelets.

The Journal of laboratory and clinical medicine·1995
Same author

Pseudomonas cepacia pseudobacteraemia.

The Journal of hospital infection·1993
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Dexfenfluramine, a serotonin agonist, effectively reduces food intake and modifies eating behavior. Clinical studies show it aids weight reduction in obese individuals, maintaining effects long-term with good safety.

Area of Science:

  • Pharmacology
  • Obesity Research
  • Neuroscience

Background:

  • Dexfenfluramine is the dextrostereoisomer of fenfluramine.
  • It acts as a pure serotonin (5-hydroxytryptamine) agonist.
  • It lacks antidopaminergic or sympathomimetic effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of dexfenfluramine in modifying eating behavior and promoting weight loss.
  • To assess dexfenfluramine's potential as a pharmacotherapeutic agent for obesity.

Main Methods:

  • Administration of dexfenfluramine (30 mg/day) to volunteers and obese patients.
  • Combination therapy with dietary support in clinical studies.
  • Evaluation of eating behavior, food intake, and weight changes over 3-12 months.

Related Experiment Videos

Main Results:

  • Dexfenfluramine reduced motivation to eat and snacking episodes.
  • Total caloric and carbohydrate intake decreased in obese patients.
  • Mean weight reductions superior to placebo were observed over 3 months, maintained for at least 12 months.
  • No serious adverse effects were reported.

Conclusions:

  • Dexfenfluramine demonstrates significant efficacy in reducing food intake and promoting weight loss.
  • It shows potential as an 'ideal' pharmacotherapeutic agent for obesity.
  • Further long-term studies are needed to confirm efficacy, safety, and define optimal indications, particularly for severe, refractory obesity cases.